drugset
drugset / Trial / NCT07275606

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

NCT07275606 ↗

Phase 1/2 Recruiting 44 enrolled ViiV Healthcare
Non-randomizedSequentialOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.

Timeline

Start
2026-04-15
Primary completion
2029-10-10
Completion
2029-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabotegravir Small molecule — Oral

Indications

HIV infectious disease